Mertens Laura S, Meinhardt Wim, Rier Walther B, Nooter Ronald I, Horenblas Simon
Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Urol Int. 2012;89(3):332-6. doi: 10.1159/000341900. Epub 2012 Sep 5.
To report our experience with symptomatic extravasation of intravesical chemotherapy administered within 24 h after transurethral resection (TUR) over the past 10 years.
We identified all consecutive patients who presented with symptomatic extravasation of intravesical chemotherapy following TUR between 2001 and 2011. We assessed the severity of the postoperative complications using the modified Clavien system.
We identified 9 patients (mean age 59, range 40-76 years) with symptomatic extravasation. One patient had grade II, 2 had grade IIIa, and 5 patients had grade IIIb complications according to the Clavien system. Surgery was needed in 6 of 9 patients. One required ICU management (Clavien IV). No patients died in the postoperative course.
Extravasation can cause severe complications and diagnosis is often protracted. Considering the growing practice of immediate intravesical instillations, the number of patients with symptomatic extravasation is expected to rise. An increased awareness of this possible complication is warranted.
报告过去10年经尿道前列腺电切术(TUR)后24小时内膀胱内化疗发生症状性渗漏的经验。
我们确定了2001年至2011年间所有在TUR术后出现膀胱内化疗症状性渗漏的连续患者。我们使用改良的Clavien系统评估术后并发症的严重程度。
我们确定了9例有症状性渗漏的患者(平均年龄59岁,范围40 - 76岁)。根据Clavien系统,1例患者为II级,2例为IIIa级,5例患者为IIIb级并发症。9例患者中有6例需要手术治疗。1例需要重症监护病房管理(Clavien IV级)。术后无患者死亡。
渗漏可导致严重并发症,诊断往往延迟。考虑到即刻膀胱灌注的做法越来越多,有症状性渗漏的患者数量预计会增加。有必要提高对这种可能并发症的认识。